Skip to main content
ANVS
NYSE Life Sciences

Annovis Q2 Loss Widens to $0.40/Share; Cash at $18.7M, Warrant Liability Jumps to $19.9M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$1.85
Mkt Cap
$78.702M
52W Low
$1.541
52W High
$5.5
52W Position info
20% above low
Off High info
66% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

ANVS sits 20% above its 52-week low of $1.541.

Summary

Annovis Bio reported a wider Q2 net loss of $0.40 per share, with cash at $18.7 million and a $19.9 million warrant liability. The pivotal Phase 3 Alzheimer's trial is fully enrolled with 850 patients, and topline data is expected in Q1 2027.


Key Events · Earnings and Guidance · ANVS

  • Q2 Net Loss Widens

    Net loss per share increased to $0.40 from $0.32 a year ago, driven by R&D expenses more than doubling to $12.0 million.

  • Cash Position Declines

    Cash and cash equivalents totaled $18.7 million as of June 30, 2026, down from $19.5 million at year-end 2025.

  • Warrant Liability Surges

    Warrant liability jumped to $19.9 million from $0.6 million at year-end, reflecting fair-value remeasurement of warrants issued in the May 2026 offering.

  • Phase 3 AD Trial Fully Enrolled

    Pivotal Phase 3 Alzheimer's trial enrolled 850 patients, exceeding the original target of 760; topline data expected in Q1 2027.


Analysis · ANVS · Life Sciences

Annovis Bio reported a wider Q2 net loss of $0.40 per share, up from $0.32 a year ago, driven by a more than doubling of R&D expenses to $12.0 million. Cash and cash equivalents fell to $18.7 million as of June 30, 2026, while the warrant liability surged to $19.9 million from $0.6 million at year-end, reflecting the fair-value remeasurement of warrants issued in the May 2026 offering. The company reiterated its going concern warning and highlighted full enrollment of its pivotal Phase 3 Alzheimer's trial with 850 patients, exceeding the original target of 760. Topline data from the 6-month analysis is expected in Q1 2027, with the disease-modifying readout a year later. The balance sheet shows negative stockholders' equity of $4.3 million, underscoring the company's reliance on dilutive capital raises to fund operations.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ANVS was trading at $1.85 on NYSE in the Life Sciences sector, with a market capitalization of approximately $78.7M. The 52-week trading range was $1.54 to $5.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ANVS - Latest Insights

ANVS
Nov 20, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.7559
Real-time Price: $0.730 info
Change: -$0.0259 (-3%) info
Market Cap: $44.117M info
ANVS
Nov 17, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.800
Real-time Price: $0.730 info
Change: -$0.070 (-9%) info
Market Cap: $44.117M info
ANVS
Nov 13, 2026, 4:24 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.940
Real-time Price: $0.730 info
Change: -$0.210 (-22%) info
Market Cap: $44.117M info
ANVS
Nov 06, 2026, 4:30 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $0.8799
Real-time Price: $0.730 info
Change: -$0.1499 (-17%) info
Market Cap: $44.117M info
ANVS
Nov 05, 2026, 8:05 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.8689
Real-time Price: $0.730 info
Change: -$0.1389 (-16%) info
Market Cap: $44.117M info